Treatment of drug resistant cancer
US-9399028-B2 · Jul 26, 2016 · US
US10618922B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10618922-B2 |
| Application number | US-201815927505-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 21, 2018 |
| Priority date | Sep 13, 2013 |
| Publication date | Apr 14, 2020 |
| Grant date | Apr 14, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Embodiments of the present disclosure provide for biaryl ligands (also referred to herein as “biaryl compound”), biaryl complexes, methods of making biaryl compounds, methods of making single enantiomers of these biaryl compounds, methods of use (e.g., catalysis), and the like.
Opening claim text (preview).
At least the following is claimed: 1. A composition comprising a single biaryl compound having the following structure: wherein MET is selected from a transition metal, wherein z is 1 to 3, wherein L is a ligand, wherein u is 0 or 1 to 5; wherein each of the R 5 groups is independently selected from the group consisting of: hydrogen, a halogen group, a cyclic or linear, alkyl group, an aryl group, a —OR group, and a —SR group, wherein each of R group is independently selected from the group consisting of: hydrogen, a cyclic or linear alkyl group, and an aryl group, wherein n is 1 to 5; wherein X is C or SO 2 , wherein each R 6 and R 7 group is independently selected from the group consisting of: hydrogen, a cyclic or linear alkyl group, and an aryl group, wherein when X is SO 2 , R 6 and R 7 are not present; wherein each of Q1, Q2, Q3, Q4, and Q5 is independently selected from the group consisting of C, N, O, and S, wherein at least one of Q1, Q2, Q3, Q4, and Q5 is selected from the group consisting of N, O, and S, wherein R 1 and R 2 are independently selected from the group consisting of: hydrogen, a halogen group, a cyclic or linear, alkyl group, an aryl group, a —OR group, and a —SR group; and wherein each of the R 4 groups is independently selected from the group consisting of: hydrogen, a halogen group, a cyclic or linear, alkyl group, an aryl group, a —OR group, and a —SR group, wherein m is 1 to 5; and wherein each of the R 3 groups is independently selected from the group consisting of: hydrogen, a cyclic or linear, alkyl group, an alkoxide, a phenoxide, an aryl group, and a substituted amine. 2. The composition of claim 1 , wherein each R 5 is halogen, wherein two of Q1, Q2, Q3, Q4, and Q5 are N, wherein X is C, and wherein each R 3 is an aryl group. 3. The composition of claim 2 , wherein Q2 and Q5 are N. 4. The composition of claim 2 , wherein each R 3 is a phenyl group. 5. The composition of claim 1 , wherein each R 5 is fluorine. 6. The composition of claim 1 , wherein the transition metal is selected from the group consisting of: Fe, Co, Ni, Ru, Rh, Pd, Os, Ir, Pt, Cu, and Au. 7. The composition of claim 1 , wherein the ligand is selected from the group consisting of: amide, phenolate, thiolate, halogen, carboxylate, acetylacetonate, phosphine, phosphite, and phosphoramidite. 8. A composition comprising: a single biaryl compound having the following structure: wherein MET is selected from a transition metal, wherein z is 1 to 3, wherein L is a ligand, wherein u is 0 or 1 to 5; wherein each of the R 5 groups is independently selected from the group consisting of: hydrogen, a halogen group, a cyclic or linear, alkyl group, an aryl group, a —OR group, a —SR group, wherein each of R group is independently selected from the group consisting of: hydrogen, a cyclic or linear alkyl group, and an aryl group, wherein n is 1 to 5; wherein X is C or SO 2 , wherein each R 6 and R 7 group is independently selected from the group consisting of: hydrogen, a cyclic or linear, alkyl group, and an aryl group, wherein when X is SO 2 , R 6 and R 7 are not present; wherein R 1 and R 2 are independently selected from the group consisting of: hydrogen, a halogen group, a cyclic or linear, alkyl group, an aryl group, a —OR group, and a —SR group; wherein each of the R 4 groups is independently selected from the group consisting of: hydrogen, a halogen group, a cyclic or linear, alkyl group, an aryl group, a —OR group, and a —SR group, wherein m is 1 to 5; and wherein each of the R 3 groups is independently selected from the group consisting of: hydrogen, a cyclic or linear, alkyl group, an alkoxide, a phenoxide, an aryl group, and a substituted amine. 9. The composition of claim 8 , wherein X is C, wherein each R 3 is a phenyl group, and wherein each R 5 is fluorine. 10. The composition of claim 8 , wherein the transition metal is selected from the group consisting of: Fe, Co, Ni, Ru, Rh, Pd, Os, Ir, Pt, Cu, and Au. 11. The composition of claim 8 , wherein the ligand is selected from the group consisting of: amide, phenolate, thiolate, halogen, carboxylate, acetylacetonate, phosphine, phosphite, and phosphoramidite.
of -CH-CH- or -C=C- to -C=C- or -C-C- triple bond species · CPC title
Oxygen atoms · CPC title
having the nitrogen atoms in positions 1 and 3 · CPC title
Syntheses without formation of a Si-C bond · CPC title
with substituted hydrocarbon radicals, directly attached to ring carbon atoms · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.